Is Syros Pharmaceuticals, Inc. overvalued or undervalued?

As of 8 July 2024, the valuation grade for Syros Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of -0.06, an EV to EBIT of 0.12, and an EV to EBITDA of 0.13, which suggest that the company is not generating adequate returns relative to its enterprise value.
In comparison to its peers, Syros Pharmaceuticals has a less favorable EV to EBITDA ratio than Avrobio, Inc. at -2.5908 and Elicio Therapeutics, Inc. at -4.1277, highlighting its struggles in the market. The company's returns have been dismal, with a year-to-date decline of -99.74% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is significantly underperforming relative to broader market trends.